M3 Biotechnology
M3 Biotechnology develops a therapy for Alzheimer’s disease designed to stop neuron deterioration.
Facts
- HQ
- Bothell, Wash.
- Sectors
- Biotechnology, Therapeutics, Neurodegenerative diseases
Is this your organization? Claim it
Athira Pharma raises $204M in IPO at $17/share, values company at ~$670M to advance Alzheimer’s drug NDX-1017
Seattle biotech Athira Pharma raised $204 million by selling 12 million shares in a Nasdaq IPO at $17 per share, valuing the company at about $670 million as it advances its lead Alzheimer’s therapeutic NDX-1017 into late-stage development.
Athira Pharma prices IPO at $17, sells 12M shares to raise $204M; will trade as ATHA on Nasdaq
Seattle biotech Athira Pharma priced its IPO at $17 per share, selling 12 million shares to raise at least $204 million and will begin trading on Nasdaq under ticker ATHA; the company is developing NDX-1017 for neurodegenerative diseases and has no commercial products yet. Founded in 2011 and led by CEO Dr. Leen Kawas, Athira reported net losses in 2019 and H1 2020 and has raised over $100 million privately, including an $85 million Series B.
Athira Pharma raises $85M Series B to push NDX-1017 toward FDA approval for Alzheimer’s, Parkinson’s and ALS
Seattle biotech Athira Pharma raised $85 million in a Series B round to advance NDX-1017, a regenerative therapy aimed at halting or reversing nerve damage in Alzheimer’s, Parkinson’s and ALS, with preliminary trial results reported as positive and potential market availability in 2–3 years.
See all 7 stories, episodes and videos about M3 Biotechnology.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Leen Kawas Founder